Cyteir was a clinical-stage oncology company focused on the development of CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. Cyteir had CYT-0851 in development in combination with capecitabine and gemcitabine in a Phase 1/2 clinical study, including patients with advanced ovarian cancer.